MSB 7.69% $1.19 mesoblast limited

Cell Therapy News/Articles, page-17061

  1. 924 Posts.
    lightbulb Created with Sketch. 158
    well the FDA has rejected even on a 2nd Type A review.

    so unsure how you say there is no problem when the FDA categorically say there is a problem.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.